Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
株式のランク #33642
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
株価
$0.03702159
最終同期: 2024-01-29
時価総額
$7.21M
変化(1日)
-3.08%
変化(1年)
0.00%
AU
取引 Antisense Therapeutics Limited (ANP)

カテゴリー

Antisense Therapeutics Limited(ANP)の収益
Aug 2026 時点の収益 TTM: 0
Antisense Therapeutics Limited の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Antisense Therapeutics Limited の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。